Urine proteomics in kidney transplantation

Area of Science:

• Nephrology
• Transplant Immunology
• Biomarker Discovery

Background:

• Kidney transplant success relies on monitoring organ health and detecting rejection.
• Current methods like creatinine monitoring and tissue biopsies have limitations (non-specific, invasive).
• Urinary biomarkers offer a less invasive alternative for assessing allograft status.

Purpose of the Study:

• To evaluate the utility of urinary biomarkers for early detection of kidney allograft injury.
• To validate CXCL9 and CXCL10 as non-invasive indicators of acute rejection and graft function.
• To explore the potential of these biomarkers in guiding preemptive treatment strategies.

Main Methods:

• Analysis of urinary samples for specific biomarker concentrations.
• Correlation of biomarker levels with clinical outcomes, including rejection episodes and graft function.
• Validation of findings through clinical trials, such as CTOT-01.

Main Results:

• Urinary CXCL9 and CXCL10 levels are significantly correlated with acute kidney allograft rejection.
• CXCL9 has demonstrated predictive value for rejection and prognostic value for graft function.
• Monitoring these biomarkers can reduce the reliance on kidney transplant biopsies.

Conclusions:

• Urinary CXCL9 and CXCL10 are valuable non-invasive biomarkers for detecting kidney transplant rejection.
• These biomarkers enable earlier detection of rejection, potentially before creatinine levels rise.
• Utilizing urinary biomarker monitoring can optimize the use of biopsies and facilitate timely treatment.